---
title: "recent"
date: "2024-08-27"
enableToc: true
---

> get back to [[index]]
# 最近編輯的檔案

## 昨天

- 2024-08-26 18:00 [[acute myelogenous leukemia]]
- 2024-08-26 18:00 [[acute myelogenous leukemia (AML)]]
- 2024-08-26 18:00 [[AML]]
- 2024-08-26 08:55 [[starglo]]

## 更久以前

- 2024-08-25 14:49 [[glofitamab]]
- 2024-08-25 14:48 [[recent]]
- 2024-08-25 14:43 [[apollo]]
- 2024-08-25 14:38 [[acute promyelocytic leukemia (APL)]]
- 2024-08-25 14:38 [[acute myelogenous leukemia]]
- 2024-08-25 14:38 [[hematology]]
- 2024-08-25 14:37 [[ascend-cml]]
- 2024-08-24 16:00 [[treatment of chronic myelogenous leukemia (CML)]]
- 2024-08-24 15:58 [[chronic myelogenous leukemia]]
- 2024-08-24 15:29 [[Relapsed Refractory Disease of Diffuse large B-cell lymphoma]]
- 2024-08-24 15:27 [[DLBCL 2]]
- 2024-08-24 15:27 [[Diffuse large B-cell lymphoma]]
- 2024-08-24 15:27 [[DLBCL]]
- 2024-08-24 15:26 [[Genetics and Molecular Subtypes of Diffuse large B-cell lymphoma]]
- 2024-08-24 15:26 [[double-hit in DLBCL]]
- 2024-08-24 15:26 [[perseus]]
- 2024-08-24 15:25 [[bortezomib]]
- 2024-08-24 15:24 [[cassiopeia]]
- 2024-08-24 15:24 [[acalabrutinib]]
- 2024-08-24 14:35 [[smart_stop]]
- 2024-08-24 14:35 [[Tafasitamab]]
- 2024-08-24 14:35 [[l-mind]]
- 2024-08-24 14:32 [[double_hit_and_double_expressors_in_lymphoma]]
- 2024-08-24 14:26 [[polarix]]
- 2024-08-24 14:02 [[dreamm-8]]
- 2024-08-24 14:01 [[dreamm-7]]
- 2024-08-24 14:01 [[belantamab_mafodotin]]
- 2024-08-24 13:58 [[bcma_in_mm]]
- 2024-08-24 13:58 [[MM]]
- 2024-08-24 13:58 [[multiple myeloma (MM)]]
- 2024-08-24 13:58 [[multiple myeloma]]
- 2024-08-24 13:58 [[MM 2]]
- 2024-08-24 13:58 [[cutaneous T cell lymphoma]]
- 2024-08-24 13:58 [[CTCL]]
- 2024-08-24 13:58 [[CTCL 2]]
- 2024-08-24 13:58 [[Acute Myeloid Leukemia]]
- 2024-08-24 13:58 [[leukemia]]
- 2024-08-24 13:58 [[flt3_mutation_in_aml]]
- 2024-08-24 13:58 [[gilteritinib]]
- 2024-08-24 13:58 [[morpho]]
- 2024-08-24 13:58 [[treatment and prognosis of multiple myeloma (MM)]]
- 2024-08-24 13:57 [[treatment of multiple myeloma (MM)]]
- 2024-08-24 13:57 [[imroz]]
- 2024-08-24 13:51 [[types_of_flt3_mutations]]
- 2024-08-24 13:22 [[midostaurin]]
- 2024-08-24 13:21 [[gilteritinib_or_chemotherapy_for_relapsed_or_refractory_flt3-mutated_aml]]
- 2024-08-24 11:49 [[bcma]]
- 2024-08-24 11:49 [[NHL]]
- 2024-08-24 11:49 [[non-Hodgkin lymphoma (NHL)]]
- 2024-08-24 11:49 [[NHL 2]]
- 2024-08-24 11:48 [[PTCL]]
- 2024-08-24 11:48 [[PTCL 2]]
- 2024-08-24 11:48 [[peripheral T cell lymphoma]]
- 2024-08-24 10:49 [[echelon-2]]
- 2024-08-24 10:33 [[myelofibrosis]]
- 2024-08-24 10:30 [[treatment-of-myelofibrosis]]
- 2024-08-24 10:26 [[imbark]]
- 2024-08-24 10:25 [[independence]]
- 2024-08-24 10:25 [[momentum]]
- 2024-08-24 10:25 [[bet_inhibitor]]
- 2024-08-24 10:24 [[molecular_pathogenesis_of_the_myeloproliferative_neoplasms]]
- 2024-08-24 10:16 [[fedratinib]]
- 2024-08-24 10:16 [[freedom2]]
- 2024-08-24 10:10 [[mtss]]
- 2024-08-24 10:10 [[rr6]]
- 2024-08-24 09:57 [[comfort-i]]
- 2024-08-24 09:57 [[gipss]]
- 2024-08-24 09:39 [[toxicity_management_in_bispecific_antibiotics_in_multiple_myeloma]]
- 2024-08-24 09:39 [[bite_rrmm]]
- 2024-08-24 09:38 [[frequency_and_duration_of_bispecific_antibiotics]]
- 2024-08-24 09:25 [[monumental-1]]
- 2024-08-24 09:22 [[gprc5d]]
- 2024-08-24 09:21 [[bispecific_antibodies_for_relapse_and_refractory_multiple_myeloma]]
- 2024-08-24 09:21 [[magnetismm-3]]
- 2024-08-24 09:20 [[elranatamab]]
- 2024-08-24 09:20 [[bite]]
- 2024-08-24 09:17 [[majestec-1]]
- 2024-08-24 09:16 [[covid-19_and_majestec-1]]
- 2024-08-24 09:14 [[toxicity_in_majestec-1]]
- 2024-08-23 21:17 [[.md]]
- 2024-08-21 16:15 [[anemia]]
- 2024-08-21 16:15 [[clinical manifestations-anemia]]
- 2024-08-21 16:15 [[Diagnostic evaluation-anemia]]
- 2024-08-21 16:15 [[Approach to anemia and common causes]]
- 2024-08-21 16:15 [[hemolytic anemias]]
- 2024-08-21 16:14 [[Evaluation-dyspnea]]
- 2024-08-21 16:13 [[systemic sclerosis and scleroderma disorders]]
- 2024-08-21 16:13 [[SSc]]
- 2024-08-21 16:13 [[systemic sclerosis]]
- 2024-08-21 16:13 [[CREST Syndrome]]